Topic: translational research
The creation of the latest outpost of the BRIDGE model sees Evotec team up with Integra Holdings and Yissum to help researchers at Hebrew University.
CRUK is set to invest $25 million in SV’s new biotech fund and work with its new partner to pick out research to develop externally.
News of the hires comes weeks after Schrödinger pulled in more cash to fund its evolution into a biotech with an internal pipeline.
Deerfield is contributing up to $65 million to create a company to speed the route to market for drugs discovered at the University of Illinois at Chicago.
Deerfield Management and Harvard University are setting up a new company dubbed Lab1636, with $100 million in backing from Deerfield.
The move sees Saha end his near-10-year spell away from Big Pharma for the chance to run Bristol-Myers’ translational medicine operation.
Francis Collins remains NIH chief, but billions of dollars in cuts could be on the way.
Bristol-Myers Squibb will tap into the immuno-oncology expertise of the Parker Institute and Cancer Research Institute (CRI) in a bid to accelerate clinical trials of new cancer medicines.
A trio of pharmas have bought into the vision of early startup Blade Therapeutics. Pfizer Venture Investments, Novartis Institutes for Biomedical Research and Bristol-Myers Squibb all came in to the $45 million Series B round for the startup, which aims to address novel targets in fibrotic disease. It expects to get into the clinic with this financing